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Abstract  
AIM: The research was conducted by genotyping two Human Leukocyte Antigen (HLA) gene 
classes. The main objective of this research was to investigate distribution and frequency of the 
allelic groups, genotypes and haplotypes in the gene loci of HLA class I (HLA-A*, -B*, -C*) and HLA 
class II (HLA-DRB1*, -DQB1*) in patients included in the program of cadaveric renal 
transplantation.  
MATERIAL AND METHODS: Our study covered 186 blood samples of patients who are registered 
on the list for cadaveric renal transplantation in Federation of Bosnia and Herzegovina and included 
59 control, healthy unrelated individuals. For the HLA typing, we have used three different methods: 
micro lymphocyte cytotoxicity test (MLCT), Polymerase Chain Reaction (PCR) – Sequence Specific 
Primers (SSP) and PCR – Sequence-Specific Oligonucleotides (SSO) or Luminex technology. All 
patients and cadaveric donors were tested using the three methods because the system is 
polymorphic. 
 
RESULTS: Analysis of the results of genotyping HLA class I gene loci identified dominant HLA-
A*02, HLA-B*35, HLA-C*07 allelic groups. Analysis of the HLA class II gene loci genotyping 
showed that HLA-DRB1*11 and HLA-DQB1*03 loci had the highest incidence in HLA class II. 
CONCLUSION: Based on our results and previous research, there were no observed differences 
between allelic frequencies and genotypes of healthy people and people with ESRD. Differences 
between allelic groups occurred, but they were not statistically significant, except HLA-C*01 (p = 
0.020). 
 
 
 
 
Introduction 
 
The main problem with renal transplantation is 
the lack of suitable dead donors. The improvements in 
molecular genotyping methods, diagnostics and 
therapy for maintaining transplants, upgrade the 
transplantation process, however, the number of dead 
donors is not increasing, while transplantation lists 
and the need for dead transplants continues to grow 
each year [1]. Kidney transplants from live donors 
produce better results, including faster rehabilitation 
and better success rate. Another advantage is the 
increase in the number of available organs. Higher 
tissue HLA matching between donors and recipients 
contributes to the longer survival of transplanted 
organs [2]. Many transplant centres are limited to 
living organ donors only. When the donors are divided 
into groups by degree of HLA compatibility with the 
organ recipient, a better result in the survival of 
transplant has been achieved in the cases of higher 
HLA compatibility. This fact is especially true when the 
unrelated persons (or distant relatives) are kidney 
donors [3, 4]. Living organ transplantation should be 
considered for each organ recipient. MHC antigens, 
which have proven to be important in kidney 
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transplantation, are HLA-A, HLA-B and HLA-DR 
markers. As these antigens were determined by the 
genes of both parents, at least six antigens of the 
recipient (2A, 2B and 2DR) must correspond with the 
antigens of the potential donor [5]. If the kidney has 
been taken from a family member, parents or siblings, 
it is necessary that there is a correspondence in three 
loci, and partial coincidence in less important, but 
other present genes HLA-C, HLA-DP and HLA-DQ [6]. 
Value of the haplotype synchronizing (0, 1, 2) was 
determined clinically: siblings with two identical 
haplotypes can expect survival of 90% of transplants 
after one year, parents and siblings with the same 
haplotype after one year achieved graft survival of 
75%, and members of the same family without equal 
haplotypes achieve survival of 50% of the grafts after 
one year [7]. The main problem in transplantation is 
the immune response of T and B lymphocytes of the 
host [8]. The most preferred method for the prevention 
of transplant rejection is achieving sufficient antigen 
matching between donor and recipient, as with 
identical twins. Good acceptance of the transplanted 
tissue or organ is already achieved if the donor and 
recipient are matched in MHC-II class of antigens (in 
particular HLA-DR) since they directly activate T-
helper lymphocytes of the recipient [9, 10]. HLA 
antigens are the main target of immune response 
which leads to the rejection of transplanted organs. 
For the purpose of transplantation, a state of the 
histocompatibility between donor and recipient exists 
only when the immune response is absent or 
controlled to foreign graft survive [11]. The reaction of 
transplant rejection is an immune response, directed 
primarily towards the molecules of the main 
histocompatibility system or MHC antigens and other 
mismatched graft antigens [12, 13].  
The main objective of this research was 
analysis of distribution and frequency of the allelic 
groups, genotypes and different haplotypes in the 
gene loci of HLA class I (HLA-A*, -B, -C*) and HLA 
class II (HLA-DRB1*, -DQB1*) in patients who have 
been included in the program of cadaveric renal 
transplantation in Federation of Bosnia and 
Herzegovina (FB&H) for period 2007-2012. 
 
 
Materials and Methods 
  
The sample included 186 patients. All patients 
were in End Stage Renal Disease (ESRD) who were 
included in the program of cadaveric kidney 
transplantation in FB&H, and they are not related by 
blood kinship relations. Research covered patients 
from 9 hemodialysis center: Sarajevo (39 male; 16 
women), Zenica (29 male; 12 women), Bihać (13 
male; 11 women), Tešanj (13 male; 10 women); 
Travnik (8 male; 5 women), Mostar +Konjic (4 male; 4 
women), Živinice + Gračanica (8 male; 1 women), 
Odžak (6 male; 2 women). Mean age was 49 ± 7 
years. Our research on patients was undertaken in 
compliance with all applicable guidelines, which aim to 
ensure the proper implementation of the safety of 
persons participating in the scientific research, 
including Fundamentals of Good Clinical Practice, 
Declaration of Helsinki 1975, as revised in 2008, and 
in the accordance with the approval of the Ethics 
Committee of the Institute (Approval No. 01-3-3558 
23.6.2016). Genotyping included 59 healthy 
individuals that are not related to the patients; they 
represented control group.
 
 
HLA genotyping 
 Samples of venous blood were taken into vacutainer 
tubes with anticoagulant heparin (serological 
analysis), and samples of venous blood were taken 
into vacutainer tubes with anticoagulant EDTA 
(ethylene diamine tetra acetyl acid – molecular 
analysis). Isolation of DNA was carried out using the 
kit for DNA, Ready – DNA Spin Kit (Inno-train, 
Germany). The HLA genotyping was performed by 
using three different methods: 1) phenotyping of HLA 
class I (A, B and C) was done by using micro 
lymphocyte cytotoxicity test (MLCT); 2) genotyping of 
HLA class I (HLA-A*, -B* and -C*) and HLA class II 
(HLA-DRB1* and -DQB1*) was performed by low 
resolution or by using the Polymerase Chain Reaction 
(PCR) qualitative detection of sequential specific PCR 
products by agarose gel electrophoresis (method is 
based on the PCR-SSP or Sequence Specific 
Primers); 3) genotyping of HLA class I (HLA-A*, -B* 
and -C*) and HLA class II (HLA-DRB1* and -DQB1*) 
was also performed by low resolution, using 
asymmetric PCR with different primers for each 
sample. After amplification of the PCR products 
labelled with biotin, they were mixed and bind to 
complementary probes during hybridization process 
(method based on PCR-SSO or Sequence-Specific 
Oligonucleotides). This technology is also called 
Luminex technology or technology of fluoroanalyser 
with microspheres.
 
 
Statistical analysis 
 The frequency of genotypes, gene variants 
was estimated according to estimation-maximization 
(EM) algorithm which has been implemented in a 
computer software PowerMarker v3.25 (Bioinformatic 
program, Raleigh, NC, USA) and OpenEpi v3.01. [14]. 
Software for calculating risk ratios (OR) using 2x2 
contingency tables was also used. To calculate the 
statistical significance of the differences in the 
frequencies of gene variants, and genotypes of the 
control group and the patients, the Fisher accuracy 
test, with P >0.05 was used. 
 
 Fejzić et al. Genotyping of Human Leukocyte Antigens in Bosnia and Herzegovina 
______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2017 Feb 15; 5(1):1-5.                                                                                                                                                                    3 
 
 Results 
  
The frequencies of allelic groups of HLA class 
I (HLA-A*, -B*, -C*) are shown in Table 1. The highest 
frequency of the allelic groups of HLA-A* gene locus 
had HLA-A*02 (0.2930) in patients and control group 
HLA-A* (0.2797). The lowest frequency allelic groups 
were HLA-A*30 and A*31, while they weren't recorded 
in the control group. 
Table 1: Frequency of allelic groups HLA-A*, HLA-B* and HLA-
C* between control and experimental group 
 
a) HLA-A* allelic groups 
n Patients 2n Frequency 
fa 
Control 2n 
 
Frequency 
fa 
p-values 
1. A*01 68 0.1828 A*01 17 0.1441 0.277 
2. A*02 109 0.29301 A*02 33 0.2797 0.717 
3. A*03 39 0.10484 A*03 10 0.0847 0.503 
4. A*11 23 0.06183 A*11 12 0.1017 0.127 
5. A*24 36 0.09677 A*24 13 0.1102 0.654 
6. A*25 13 0.03495 A*25 4 0.0339 0.956 
7. A*26 26 0.06989 A*26 9 0.0763 0.807 
8. A*30 9 0.02419 A*30 / - - 
9. A*31 9 0.02419 A*31 / - - 
10. A*32 12 0.03226 A*32 4 0.0339 0.929 
 
b) HLA-B* allelic groups 
n Patients 2n Frequency 
fa 
Control 2n 
 
Frequency 
fa 
p-values 
1. B*07 21 0.05645 B*07 4 0.0339 0.318 
2. B*08 34 0.0914 B*08 8 0.0678 0.401 
3. B*13 15 0.04032 B*13 2 0.0169 0.218 
4. B*18 27 0.07258 B*18 11 0.0932 0.445 
5. B*27 15 0.04032 B*27 5 0.0424 0.920 
6. B*35 45 0.12097 B*35 17 0.1441 0.477 
7. B*38 17 0.0457 B*38 4 0.0339 0.572 
8. B*44 42 0.1129 B*44 8 0.0678 0.134 
9. B*51 54 0.14516 B*51 15 0.1271 0.591 
10. B*57 17 0.0457 B*57 5 0.0424 0.820 
 
c) HLA-C* allelic groups 
n Patients 2n Frequency 
fa 
Control 2n 
 
Frequency 
fa 
p-values 
1. C*01 41 0.11022 C*01 5 0.0424 0.020* 
2. C*02 38 0.10215 C*02 8 0.0678 0.239 
3. C*03 21 0.05645 C*03 8 0.0678 0.638 
4. C*04 66 0.17742 C*04 22 0.1864 0.813 
5. C*05 20 0.05376 C*05 4 0.0339 0.371 
6. C*06 41 0.11022 C*06 12 0.1017 0.781 
7. C*07 120 0.32258 C*07 36 0.3051 0.626 
8. C*08 5 0.01344 C*08 1 0.0085 0.667 
9. C*12 9 0.02419 C*12 15 0.1271 <0.001* 
10. C*14 3 0.00806 C*14 2 0.0169 0.400 
*, Statistically different in comparison with control. 
Among allelic groups of HLA-B* gene locus 
the most usual allelic groups were HLA-B*51 (0.1451) 
in patients group and HLA-B*35 (0.1209) in control 
group, while allelic groups HLA-B*13 and B*27 in 
patients group and allelic groups HLA-B*13 in control 
group had the lowest frequency.  
  The highest frequency of HLA-C* gene locus 
had following allelic group HLA-C*04 (0.1774) in 
patients group and HLA-C*07 (0.3051) at healthy, 
control group while the lowest frequency value had 
allelic group C*14 in patients group and C*08 in 
control group. Significant differences between both 
groups were recorded for HLA-C*01 and C*12 allelic 
groups. 
  Genotyping of HLA class II gene loci 
determined presence HLA-DRB1*11 allele group with 
highest frequencies of patients group and HLA-
DRB1*13 in control group. Results of analysis of 
DRB1* gene locus are shown in Table 2.  
   The highest frequency within the HLA-DQB1* gene 
locus had allelic group DQB1*03 (0.3333), and HLA-
DQB1* 06 is very frequently in both group. It was not 
noticed an absence of any allelic group in HLA-DQB1* 
gene locus. Results of analysis of DQB1* allelic 
groups are shown in Table 2.  
Table 2: Frequency of HLA-DRB1* and HLA-DQB1* gene loci 
between control and experimental group  
HLA-DRB1* 
n Patients 2n Frequency 
fa 
Control 2n 
 
Frequency 
fa 
p-values 
1. DRB1*01 45 0.12097 DRB1*01 13 0.1102 0.733 
2. DRB1*03(17) 43 0.11559 DRB1*03(17) 16 0.1356 0.531 
3. DRB1*04 47 0.12634 DRB1*04 9 0.0763 0.110 
4. DRB1*07 29 0.07796 DRB1*07 9 0.0763 0.950 
5. DRB1*08 14 0.03763 DRB1*08 5 0.0424 0.812 
6. DRB1*11 57 0.15323 DRB1*11 15 0.1271 0.443 
7. DRB1*13 38 0.10215 DRB1*13 20 0.1695 0.030* 
8. DRB1*14 22 0.05914 DRB1*14 5 0.0424 0.751 
9. DRB1*15 36 0.09677 DRB1*15 13 0.1102 0.654 
10. DRB1*16 29 0.07796 DRB1*16 11 0.0932 0.580 
 
HLA-DQB1* 
n Patients 2n Frequency 
fa 
Control 2n 
 
Frequency 
fa 
p-values 
1. DQB1*02 68 0.1828 DQB1*02 22 0.1864 0.919 
2. DQB1*03 124 0.48334 DQB1*03 36 0.3050 0.427 
3. DQB1*04 12 0.03226 DQB1*04 3 0.0254 0.702 
4. DQB1*05 106 0.28495 DQB1*05 28 0.2373 0.200 
5. DQB1*06 62 0.16667 DQB1*06 29 0.2458 0.028* 
*, Statistically different in comparison with control. 
   HLA-A* gene locus analysis revealed 63 
different HLA-A* genotypes for 186 observed patients 
(Table 3.). The most common genotypes were HLA-
A*02/A*02 (0.1022), and HLA-A*01/A*02 (0.0753).  
Table 3: Frequency of HLA-A* genotypes between control and 
experimental group  
HLA-A* genotypes 
n Patients n Genotype 
frequency 
Control n 
 
Genotype 
frequency 
p-values 
1. A*01/A*01 7 0.0376 A*01/A*01 / / - 
2. A*01/A*02 14 0.0753 A*01/A*02 5 0.0847 0.812 
3. A*01/A*03 11 0.0591 A*01/A*03 / / - 
4. A*01/A*24 8 0.043 A*01/A*24 3 0.0508 0.800 
5. A*01/A*26 6 0.0323 A*01/A*26 1 0.0169 0.460 
6. A*02/A*02 19 0.1022 A*02/A*02 4 0.0678 0.424 
7. A*02/A*03 14 0.0753 A*02/A*03 4 0.0678 0.848 
8. A*02/A*11 8 0.043 A*02/A*11 5 0.0847 0.107 
9. A*02/A*24 11 0.0591 A*02/A*24 4 0.0678 0.809 
10. A*02/A*26 7 0.0376 A*02/A*26 3 0.0508 0.654 
 
  Within the HLA-B* gene locus, in 186 
patients, an analysis revealed 96 different genotypes 
(Table 4). The most common genotypes were HLA-
B*35/B*44 (0.0484) and HLA-B*08/51*B (0.0376). In 
the control group, the most frequent genotypes in B* 
locus are HLA-B*08/51 and HLA-B*35/51 (0.0508). 
Table 4: Frequency of HLA-B* genotypes between control and 
experimental group  
HLA-B*  genotypes 
n Patients n Genotype 
frequency 
Control n 
 
Genotype 
frequency 
p-values 
1. B*07/B*35 5 0.0269 B*07/B*35 1 0.0169 0.667 
2. B*07/B*44 4 0.0215 B*07/B*44 / / - 
3. B*08/B*44 6 0.0323 B*08/B*44 / / - 
4. B*08/B*51 7 0.0376 B*08/B*51 3 0.0508 0.654 
5. B*13/B*18 6 0.0323 B*13/B*18 1 0.0169 0.538 
6. B*18/B*51 4 0.0215 B*18/B*51 1 0.0169 0.829 
7. B*35/B*35 5 0.0269 B*35/B*35 1 0.0169 0.667 
8. B*35/B*44 9 0.0484 B*35/B*44 2 0.0339 0.639 
9. B*35/B*51 5 0.0269 B*35/B*51 3 0.0508 0.366 
10. B*38/B*44 4 0.0215 B*38/B*44 / / - 
11. B*38/B*51 4 0.0215 B*38/B*51 1 0.0169 0.829 
12. B*39/B*51 4 0.0215 B*39/B*51 1 0.0169 0.829 
13. B*51/B*51 6 0.0323 B*51/B*51 / / - 
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  Within the HLA-C* gene locus it was found 37 
different genotypes (Table 5), the most common 
genotypes were HLA-C*07/07*C (0.1774), HLA-
C*04/04*C (0.1022) and HLA-C*04/07*C (0.0699) in 
patients group. In the control group, the most frequent 
genotype is HLA-C*07/07*C (0.1356). 
Table 5: Frequency of HLA-C* genotypes between control and 
experimental group 
HLA-C*  genotypes 
n Patients n Genotype 
frequency 
Control n 
 
Genotype 
frequency 
p-values 
1. C*01/ C*01 10 0.0538 C*01/ C*01 / / - 
2. C*02/ C*02 7 0.0376 C*02/ C*02 / / - 
3. C*02/ C*07 7 0.0376 C*02/ C*07 1 0.0169 0.436 
4. C*03/ C*07 7 0.0376 C*03/ C*07 1 0.0169 0.436 
5. C*04/ C*04 19 0.1022 C*04/ C*04 3 0.0508 0.230 
6. C*04/ C*07 13 0.0699 C*04/ C*07 5 0.0847 0.703 
7. C*07/ C*07 33 0.1774 C*07/ C*07 8 0.1356 0.453 
8. C*01/ C*06 7 0.0376 C*01/ C*06 / / - 
9. C*06/ C*06 7 0.0376 C*06/ C*06 / / - 
10. C*06/ C*07 12 0.0645 C*06/ C*07 5 0.0847 0.086 
 
 Within the HLA-DRB1* gene locus it was 
determined the presence of 58 different genotypes, 
including the most common HLA-DRB1*01/DRB1*11 
(0.0430), HLA-DRB1*04/DRB1*11 and HLA-
DRB1*13/DRB1*16 genotype (0.0376) in patients 
group.  
Table 6: Frequency of HLA-DRB1* genotypes between control 
and experimental group 
HLA-DRB1* genotypes 
n Patients n 
Genotype 
frequency 
Control 
n 
 
Genotype 
Frequency 
p-
values 
1. DRB1*01/ DRB1*11 8 0.043 DRB1*01/ DRB1*11 / / - 
2. DRB1*01/ DRB1*04 6 0.0323 DRB1*01/ DRB1*04 1 0.0169 0.538 
3. 
DRB1*03(17)/ 
DRB1*11 
6 0.0323 
DRB1*03(17)/ 
DRB1*11 
1 0.0169 0.538 
4. 
DRB1*03(17)/ 
DRB1*16 
6 0.0323 
DRB1*03(17)/ 
DRB1*16 
2 0.0339 0.950 
5. DRB1*04/DRB1*07 6 0.0323 DRB1*04/DRB1*07 3 0.0508 0.508 
6. DRB1*04/ DRB1*11 7 0.0376 DRB1*04/ DRB1*11 2 0.0339 0.894 
7. DRB1*11/ DRB1*14 6 0.0323 DRB1*11/ DRB1*14 3 0.0508 0.508 
8. DRB1*11/ DRB1*15 6 0.0323 DRB1*11/ DRB1*15 1 0.0169 0.538 
9. DRB1*13/ DRB1*16 7 0.0376 DRB1*13/ DRB1*16 / / - 
 
  Research results within the HLA-DQB1* gene 
locus revealed 27 different genotypes. The most usual 
genotypes were HLA-DQB1*03/DQB1*05 (0.2204) 
and HLA-DQB1*02/DQB1*03 (0.1667) in patients 
group. The genotype HLA-DQB1*02/DQB1*03 is the 
most frequent in the control group.   
Table 7: Frequency of HLA-DQB1* genotypes between control 
and experimental group 
HLA-DQB1* genotypes 
n Patients n 
Genotype 
frequency 
Control 
 
n 
 
Genotype 
frequency 
p-
values 
1. 
DQB1*02/ 
DQB1*02 
8 0.043 
DQB1*02/ 
DQB1*02 
/ / - 
2. 
DQB1*02/ 
DQB1*03 
31 0.1667 
DQB1*02/ 
DQB1*03 
10 0.1694 0.959 
3. 
DQB1*02/ 
DQB1*05 
21 0.1129 
DQB1*02/ 
DQB1*05 
4 0.0678 0.318 
4. 
DQB1*03/ 
DQB1*03 
21 0.1129 
DQB1*03/ 
DQB1*03 
3 0.0508 0.162 
5. 
DQB1*03/ 
DQB1*05 
41 0.2204 
DQB1*03/ 
DQB1*05 
7 0.1186 0.086 
6. 
DQB1*03/ 
DQB1*06 
22 0.1182 
DQB1*03/ 
DQB1*06 
8 0.1356 0.723 
7. 
DQB1*05/ 
DQB1*05 
13 0.0699 
DQB1*05/ 
DQB1*05 
6 0.1017 0.426 
8. 
DQB1*05/ 
DQB1*06 
14 0.0753 
DQB1*05/ 
DQB1*06 
3 0.0508 0.520 
 
Discussion 
  
HLA class I molecules can be found on the 
surface of all cells that contain the nucleus, while 
class II of HLA molecules can be constitutively found 
on the surface of certain types of cells (dendritic cells, 
macrophages, B-lymphocytes. HLA-DR (not HLA-DQ,        
-DP, or -DM) is abundantly expressed on the 
endothelial cells of peritubular and glomerular 
capillaries [15]. 
Table 8: Frequency of allelic group with Odds Ratio (OR) and p-
values between control and patients group 
  
Allelic groups 
 
2n 
Patients 
Allele frequency 
 
2n 
Control 
Allele frequency 
 
OR 
 
p-values 
HLA-C*01 41 0.11022 5 0.0424 2.799 0.020 
HLA-C*12 9 0.02419 15 0.1271 0.1702 0.0000063 
HLA-DRB1*13 38 0.10215 20 0.1695 0.5575 0.030 
HLA-DQB1*06 62 0.16667 29 0.2458 0.6138 0.0280 
 
 The explanation for the improved survival of 
kidney allografts in which HLA have good congruence 
was: lower occurrence of anti-HLA antibodies [16], 
lower occurrence of alloreactive CD4+ T-cells or 
absence of direct CD4+ T-cell response to HLA-DR 
matched graft [17], fewer peptide epitopes stimulate 
response of T-helper cells of "indirect way" which 
includes chronic rejection of allograft [18]. HLA 
matching in HLA-A, HLA-B and HLA-DR loci 
increases the likelihood of developing a donor 
antigen-specific regulatory T-cells [19]. 
Benefits of HLA matching has an impact on 
different outcomes in terms of number of days spent 
in hospital, failure of graft function [20, 21], episodes 
of rejection, the one-year and three-year levels of 
serum creatinine [22], on prediction of long-term 
outcome of the disease, on status of patients and on 
multivariate analysis [23, 24]. 
Chronic renal failure (CRF) leads in most 
cases to ESRD, with final result – kidney 
transplantation process. There is an interest to assess 
connection of class I and II of HLA antigens with 
ESRD or CRF renal diseases [25]. 
In hemodialysis patients that are the part of 
cadaveric renal transplantation program in FB&H it 
was observed that the HLA antigens with the greatest 
frequency were: HLA-A*02 = 0.29301, HLA-B*51 = 
0.14516, HLA-C*07 = 0.32258, HLA-DRB1*11 = 
0.15323 and HLA-DQB1*03 = 0.48334. The antigens 
that showed in control group greatest frequency were: 
HLA-A*02= 0.2797, HLA-B*35= 0.1441, HLA-C* = 
0.03051, HLA-DRB1*13 = 0.1695 and HLA-DQB1*03 
= 0.3050. In the analysis of allelic groups in each 
locus, with estimation of the p-value, the allelic group 
HLA-A* showed no statistically significant difference in 
the aforementioned allelic groups. Such results were 
also recorded when comparing the frequencies of 
allelic groups in HLA-B*. Locus C* showed a 
statistically significant difference in the frequency of 
the allelic HLA-C*01 with p = 0.020 and OR = 2.601, 
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that is considered as an allelic group of high risk, and 
it showed a difference in the allelic HLA-C*12 with p = 
0.0000679. Although the OR value is 0.190, this allelic 
group can't be considered protective. The HLA-DRB1* 
locus also showed statistical significance in 
frequencies in the allelic HLA-DRB1*13 (p = 0.030) 
with OR = 0.6027, and it is not at risk of developing 
ESRD. The allelic group HLA- DQB1*06 showed 
statistical significance (p = 0.028) and OR = 0.6138, 
and it is not considered as a group of high risk, as 
shown in Table 3.  
Our research covered hemodialysis patients 
included in program of cadaveric renal transplantation 
in FB&H. The HLA class I (HLA-A*, -B*, -C*) 
genotypes with the highest incidence were: A*02/A*02 
= 0.1022, B*35/B*44 = 0.0484, C*07/07 = 0.1774. 
HLA class II genotypes with highest incidence were: 
DRB1*01/DRB1*11 = 0.043 and DQB1*03/DQB1*05 = 
0.2204.  
Based on our results and previous research, 
there were no observed differences between allelic 
frequencies and genotypes of healthy people and 
people with ESRD. Differences between allelic groups 
occurred, but they were not statistically significant, 
except HLA-C*01, p = 0.020. 
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